Drugs / r-metHuSCF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01016795 Comparator | Jan 1999 → Nov 2000 | lymphoma | Aalborg University Hospital | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | r-metHuSCF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01016795 ↗ |
| Known as | Ancestim | “The hypothesis is that elimination of chemotherapy from the priming regimen may decrease the overall toxicity and the ability to collect a sufficient autograft which, however,...” NCT01016795 ↗ |
| Modality | Protein / enzyme biologic | “Stem cell factor (SCF) is a glycoprotein growth factor that acts on haematopoietic blood cell progenitors.” NCT01016795 ↗ |
| Route | Subcutaneous | “SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A)” NCT01016795 ↗ |